Literature DB >> 11241889

Abnormalities in apo B-containing lipoproteins in diabetes and atherosclerosis.

G H Tomkin1, D Owens.   

Abstract

Atherosclerosis is the major cause of death in patients with diabetes. Low-density lipoprotein (LDL) being the most important cholesterol-carrying lipoprotein has been studied extensively in both diabetes and non-diabetes. This paper reviews the literature but also focuses on the precursors of LDL and in particular the postprandial apo B-containing lipoproteins. Abnormalities in the postprandial lipoproteins and alteration in chylomicron assembly and clearance are discussed and the evidence presented suggesting the importance of dysregulation of these lipoproteins in atherosclerotic progression. The relationship between chylomicron production in the intestine and hepatic release of very low-density lipoproteins (VLDL) is explored, as is the interrelationship between clearance rates of these lipoproteins. The size of LDL influences its atherogenicity. VLDL composition and size in relation to its influence on LDL is discussed. The effect of diet on the composition of lipoproteins and the relationship between fatty acid composition and clearance is reviewed. Evidence that diabetic control beneficially alters lipoprotein composition is presented suggesting how improved diabetic control may reduce atherosclerosis. The review concludes with a discussion on the effect of the apo B-containing lipoproteins and their modification through glycation and oxidation on macrophage and endothelial function. Copyright 2001 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11241889     DOI: 10.1002/dmrr.179

Source DB:  PubMed          Journal:  Diabetes Metab Res Rev        ISSN: 1520-7552            Impact factor:   4.876


  15 in total

1.  Conway Memorial Lecture 2002. The dyslipidaemia of diabetes: lessons in the pathogenesis of atherosclerosis.

Authors:  G H Tomkin
Journal:  Ir J Med Sci       Date:  2002 Oct-Dec       Impact factor: 1.568

2.  Robert Graves Memorial Lecture. Diabetes and atherosclerosis--a gut review.

Authors:  G H Tomkin
Journal:  Ir J Med Sci       Date:  2002 Apr-Jun       Impact factor: 1.568

Review 3.  Role of the gut in modulating lipoprotein metabolism.

Authors:  Alan A Hennessy; R Paul Ross; Gerald F Fitzgerald; Noel Caplice; Catherine Stanton
Journal:  Curr Cardiol Rep       Date:  2014-08       Impact factor: 2.931

Review 4.  Treatment of Dyslipidemias to Prevent Cardiovascular Disease in Patients with Type 2 Diabetes.

Authors:  Maryam Khavandi; Francisco Duarte; Henry N Ginsberg; Gissette Reyes-Soffer
Journal:  Curr Cardiol Rep       Date:  2017-01       Impact factor: 2.931

5.  Glycation of low-density lipoproteins by methylglyoxal and glycolaldehyde gives rise to the in vitro formation of lipid-laden cells.

Authors:  B E Brown; R T Dean; M J Davies
Journal:  Diabetologia       Date:  2005-01-20       Impact factor: 10.122

6.  Mfge8 regulates enterocyte lipid storage by promoting enterocyte triglyceride hydrolase activity.

Authors:  Amin Khalifeh-Soltani; Deepti Gupta; Arnold Ha; Jahangir Iqbal; Mahmood Hussain; Michael J Podolsky; Kamran Atabai
Journal:  JCI Insight       Date:  2016-11-03

Review 7.  New dimension of statin action on ApoB atherogenicity.

Authors:  M John Chapman; Muriel Caslake; Chris Packard; Fergus McTaggart
Journal:  Clin Cardiol       Date:  2003-01       Impact factor: 2.882

8.  Renal functional reserve in patients with Type 1 diabetes mellitus.

Authors:  Jelka Zaletel; Darko Cerne; Katarina Lenart; Sabine Zitta; Günther Jürgens; Willibald Estelberger; Andreja Kocijancic
Journal:  Wien Klin Wochenschr       Date:  2004-04-30       Impact factor: 1.704

Review 9.  Diabetic dyslipidaemia: from basic research to clinical practice.

Authors:  M-R Taskinen
Journal:  Diabetologia       Date:  2003-05-28       Impact factor: 10.122

10.  Myocardial metabolism of triacylglycerol-rich lipoproteins in type 2 diabetes.

Authors:  You-Guo Niu; Rhys D Evans
Journal:  J Physiol       Date:  2009-05-11       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.